Sequenta, Inc. and iRepertoire Join Forces on Blood Cancer Testing

Published: Aug 08, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif. & HUNTSVILLE, Ala.--(BUSINESS WIRE)--Sequenta and iRepertoire announced today that Sequenta has gained exclusive rights to the iRepertoire intellectual property on novel methods of immune cell sequencing for minimal residual disease (MRD) testing. This intellectual property complements Sequenta’s existing patents on MRD, including its proprietary LymphoSIGHT™ technology. The agreement reinforces Sequenta’s patent portfolio, which strengthens Sequenta’s ability to provide future products and new features and solidifies the company’s position as the MRD market leader.

Help employers find you! Check out all the jobs and post your resume.

Back to news